Nattam, Sreenivasa R.

Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer

Catenacci, D. V. T., Junttila, M. R., Karrison, T., Bahary, N., Horiba, M. N., Nattam, S. R., Marsh, R., Wallace, J., Kozloff, M., Rajdev, L., et al. (2015) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchHedgehog Signaling Pathway Studies

Cited by 561

Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium

Kindler, H. L., Wroblewski, K., Wallace, J. A., Hall, M. J., Locker, G., Nattam, S., Agamah, E., Stadler, W. M., & Vokes, E. E. (2012) · Investigational New Drugs

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 103